IXICO plc
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Bram Goorden
- Full Time Employees
- 79
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Griffin Court London GL United Kingdom EC1A 9PN
- IPO Date
- Jan 23, 1997
- Website
- ixico.com
- Similar Companies
- Business
- IXICO plc (AIM: IXI) is a global leader in neuroscience imaging and biomarker analytics, providing AI-driven precision medicine services to biopharmaceutical companies for the discovery, development, and delivery of novel treatments targeting neurological disorders including Alzheimer's disease, Huntington's disease, Parkinson's disease, and rare neurodegenerative conditions. The company offers an end-to-end suite of specialized products and services encompassing proprietary AI imaging analytics via its TrialTracker platform for structural, molecular, and functional neuroimaging; clinical trial imaging project and site management with secure data coordination; fully compliant image and digital biomarker data management and analysis; expert scientific, technical, and operational advisory services for biomarker selection and imaging endpoints; blood-based biomarker validation support; and post-marketing surveillance analytics to monitor patient responses. These capabilities support hundreds of neurological clinical trials worldwide, leveraging an expansive network of expert imaging centers and disease-specific algorithms to de-risk drug development, enhance patient eligibility assessments, and accelerate R&D decision-making. Founded in 2004 as a spin-out from leading London academic institutions and headquartered at 4th Floor, Griffin Court, 15 Long Lane, London EC1A 9PN, United Kingdom, IXICO operates globally with clients spanning major pharmaceutical firms, innovative biotechs, scientific consortia, and non-profit organizations in the biopharmaceutical industry. Recent developments include a landmark £3.5 million four-year contract signed in November 2025 with a global pharmaceutical company for Phase 3 imaging services in a Huntington's disease trial; a £1.2 million combined new contract and extension in October 2025 for blood-based biomarker validation and an existing Alzheimer's disease trial; a £3.7 million net capital raise in H1 2025 to fund its Innovate, Lead, Scale strategy; year-end order book growth to £13.8 million for FY25 ending September 30, 2025, with £6.5 million in revenues exceeding expectations; and ongoing contract expansions reflecting strengthened biopharma commitments to rare neurological diseases.
IXICO guidance unchanged after Huntington's cancellations
IXICO guidance unchanged after Huntington's cancellations
South32’s $4.7bn Hermosa project clears key US approval as critical minerals push accelerates
IXICO lifts revenue forecast on contract wins and wider client base - UPDATE
IXICO lifts revenue forecast on contract wins and wider client base
SpaceX stock surges in hotly anticipated market debut
IXICO expands scientific network in Alzheimer's and Parkinson's disease
Percheron Therapeutics secures proposed WHO drug name for HMBD-002 cancer therapy
Walmart price target lowered by UBS as Q1 results miss elevated expectations
Bram Goorden discusses IXICO growth plans - ICYMI
Bram Goorden discusses IXICO growth plans - ICYMI
IXICO plc (PHYOF) Q2 2026 Earnings Call Transcript
Zscaler set to benefit from federal tailwinds boosting fourth quarter outlook: analysts
IXICO contract wins provide near-total revenue visibility for current year
IXICO wins £1.3 million in Alzheimer's and Huntington's contracts
UK utility investors face prolonged uncertainty after worst sell-off since privatisation era
Cavendish sees IXICO forecasts as conservative after order book hits five-year high
Cavendish sees IXICO forecasts as conservative after order book hits five-year high
IXICO targets 15% revenue growth as order book swells and strategy takes shape
Rigetti Computing tops Q1 earnings estimates as loss narrows